GlaxoSmithKline Pharmaceuticals informs about outcome of board meeting
In compliance with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), GlaxoSmithKline Pharmaceuticals has informed that the Board of Directors at its meeting held today have approved the appointment Ronojit Biswas (DIN 07684843) as the Whole-Time Director & Chief Financial Officer (CFO) of the Company for term of three years with effect from 1st April 2026 & Juby Chandy (Current CFO) to transition into a new role in GSK Group. Ronojit Biswas is not related to any of the existing Directors of the Company, and he is not debarred from holding the Office of Director by virtue of any order passed by SEBI or any other such authority. The Meeting of Board of Directors commenced at 11.00 am and concluded at 12.00 noon.
The above information is a part of company’s filings submitted to BSE.
